Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

A vizsgálat adatai

Ki végzi

RECORDATI GROUP

Azonosító

NCT07247162EU 2025-524649-28-00

A regiszteradat frissítve

2026. november 2.

Eredeti leírás

Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.A teljes eredeti leírásKevesebb

A Double-blind, Randomised, 30-week Placebo-controlled Phase IV Study to Assess the Efficacy and Safety of Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.

Bevonási feltételek: Male or female ≥ 18 years of age; Able to provide and have provided signed written informed consent prior to study participation; Diagnosis of endogenous Cushing's Syndrome; mUFC values from two 24h urinary collections > ULN and ≤ 2x ULN; Participants with uncontrolled hypertension on stable doses of BP lowering medications (for at least 4 weeks); qualifying BP measurements by ABPM taken prior to randomisation defined as: Average of 24h ABPM SBP ≥ 135 or DBP ≥ 85 mmHg; Participants under glucocorticoid replacement therapy can be recruited only if this therapy has been already stopped for at least seven days or 5 half-lives prior to screening, whichever was longer; Not taking any drug therapy for CS. The following minimum periods without these medications need to be completed before baseline assessments:; Steroidogenesis inhibitors (e.g. ketoconazole, metyrapone): 1 week; Mifepristone: 3 weeks; SC Pasireotide: 1 week; Pasireotide LAR: 3 months; Cabergoline: 4 weeks; Able to take oral medication and be willing to comply with the requirements of the study.

Kizáró feltételek: Previously treated with osilodrostat less than 12 weeks prior to start of screening; Participants who are scheduled for a surgery to treat CS within 32 weeks of randomisation to the study drug; Presence of a known "long term" history of both hypertension and diabetes (defined as both hypertension and diabetes diagnosed >10 years prior to the initial diagnosis of endogenous CS); Participants who have undergone pituitary or adrenal surgery for Cushing's syndrome within 3 months prior to screening; Pituitary radiation therapy within 3 years of screening; Ectopic ACTH syndrome or adrenocortical carcinoma with a life expectancy of <3 years or receiving chemotherapy; Having received prior mitotane treatment; Participants who are hypothyroid and not on adequate replacement therapy; History of major surgery/surgical therapy for any cause within 4 weeks before entering the study. Participants should have recovered from the surgery and be in good clinical condition before entering the study; Participation in any clinical investigation within 4 weeks prior to screening or longer if required by local regulation (Use of an investigational drug within 4 weeks prior to dosing); Occurrence of any significant acute illness within 3 weeks prior to dosing/randomisation; Known hypersensitivity to osilodrostat; Presence of any severe and/or uncontrolled medical condition or other conditions that could affect participation in the study; History of cyclic CS with fluctuating clinical manifestations; Participants who are shift workers or have conditions that can affect the measurement of late-night salivary cortisol (LNSC) or the LDDST; Poorly controlled diabetes mellitus with a baseline HbA1c > 10.5%. Participants receiving glucose lowering medications must be on stable doses for at least 4 weeks prior screening; Presence of bradycardia and/or QT-related exclusion criteria; Total bilirubin > 1.5 x ULN and ALT or AST > 3 x ULN; Female participants who are pregnant, intending to become pregnant or breastfeed during the study or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test; Participants with pseudo-CS; Participants with compression of the optic chiasm due to a macroadenoma or participants at high risk of compression of the optic chiasm (tumour within 2 mm of optic chiasm); Women of childbearing potential (WOCBP) who are unwilling to use highly effective contraception methods; Potentially unreliable or vulnerable participants (e.g. person kept in detention) and those judged by the Investigator to be unsuitable for the study.

ClinicalTrials.gov NCT07247162 · EU CTIS 2025-524649-28-00